Skip to main content
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Neuroendocrine Tumors
A Population-Based Analysis of Risk for Cancer-Specific Death in Patients with NETs
Read More
Neuroendocrine Tumors
Multicenter Analysis of Treatment Outcomes for Well-Differentiated Grade 3 NETs
Read More
Neuroendocrine Tumors
Prognostic Factor Analysis in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms
Read More
Neuroendocrine Tumors
Pilot Study of XmAb18087, an SSTR2 × CD3 Bispecific Antibody, in Advanced NETs
Read More
Neuroendocrine Tumors
ATLANT Study Results of Lanreotide Autogel + Temozolomide Combination Therapy in Progressive Thoracic NETs
Read More
Neuroendocrine Tumors
Lanreotide as Maintenance Therapy After First-Line Treatment in Patients with Nonresectable Duodeno-Pancreatic NETs
Read More
Neuroendocrine Tumors
Comparative Analysis of Octreotide Long-Acting Release versus Lanreotide in Gastroenteropancreatic NETs
Read More
Neuroendocrine Tumors
The Use of Octreotide LAR in Routine Canadian Practice: Dosing Considerations and Persistence Rates
Read More
Neuroendocrine Tumors
177Lu-Octreotate-PRRT + Temozolomide/Capecitabine in Pancreas and Updated Midgut NETs
Read More
Neuroendocrine Tumors
A Real-World Observational Study of Somatostatin Analog Use and Costs in Canada
Read More
110
111
112
113
114
115
116
Page 113 of 197
Results 1121 - 1130 of 1963
